GLG Network Survey: AI in Healthcare Systems

Please fill out the form to request access to the survey data

SURVEY DETAILS
TARGET POPULATION

For this Network Survey, GLG surveyed 70 senior executives working in healthcare across the US and Europe (UK, France, Germany, Italy and Spain).

What will you learn from this survey?

  • Respondents provided an overview of the usage of AI and machine learning in drug discovery and clinical trials.
  • Furthermore, the survey also evaluated patient outcomes, cost analysis, potential challenges in implementing AI and the regulatory environment.
  • Lastly, the experts shared their views on the competitive landscape of companies providing AI solutions for healthcare, assessing the major platforms on the basis of the range of AI solutions, ease of integration with existing systems, cost-effectiveness and support and training services.

Examples of findings:

  • Over three-in-five (61%) experts stated that AI integration with existing systems is one of the biggest barriers to adopt AI in healthcare.
  • Improved accuracy in identifying drug candidates is one of the primary benefits of using AI in drug discovery, according to over seven-in-ten (71%) experts who declared that AI is being used in drug discovery.
  • Over half of experts consider that the near-term prospects for AI integration in healthcare are enhanced interoperability between AI systems and existing healthcare infrastructure (54%), development of guidelines for data privacy and security (54%) and collaboration between technology companies and healthcare providers for tailored solutions (54%).

Deliverables

The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Alexeis Baqui, Founder and CEO at Valhalla Healthcare.

  • 1 x Individual responses (“raw data”) in Excel.
  • 1 x PPT report with aggregated data.
  • Executive summary with key takeaways and highlights from the raw data.

Sample Questions

  • What do you perceive as the biggest barriers to adopting AI solutions in healthcare?
  • In which stage of drug development do you believe AI can have the most significant impact?
  • In what ways do you think smartphones and wearables could enhance patient monitoring and care delivery?
  • How do you believe AI advancements can enhance disease onset or escalation prediction through patient personas?
  • What do you see as the main regulatory hurdles in adopting AI in healthcare?
  • In what ways are AI algorithms being trained to identify early warning signs of disease escalation, especially in asymptomatic patients?
  • What opportunities does AI in preventive care present for insurance companies in terms of risk assessment and policy structuring?
  • In your view, what impact had AI on patient outcomes in practices/institutions in your region?

Access

This survey is available to subscribers of the Healthcare (HC) sector (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

DISCLAIMER

Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription. 

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG capture in the Network Survey.

myGLG(ご契約企業様)
マイページ(アドバイザー様)
コンプライアンス専用ページ